Qu Biologics Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
17
Qu Biologics General Information
Description
Developer of a site-specific immunotherapy platform designed to restore the body's normal immune function to treat cancer and other immune-related diseases. The company's immunotherapy utilizes built-in knowledge to direct an activated innate immune response to specific organs or tissues to respond productively to any pathology that may be present at that body site, enabling medical researchers to develop a therapy that can activate and train the human immune system to fight cancer and other diseases.
Contact Information
Website
www.qubiologics.comCorporate Office
- 4475 Wayburne Drive
- Suite 305
- Burnaby, British Columbia V5G 4X4
- Canada
Corporate Office
- 4475 Wayburne Drive
- Suite 305
- Burnaby, British Columbia V5G 4X4
- Canada
Qu Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Qu Biologics Comparisons
Industry
Financing
Details
Qu Biologics Competitors (26)
One of Qu Biologics’s 26 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Novation Pharmaceuticals | Corporation | Port Coquitlam, Canada | ||||
| Cellaion | Formerly VC-backed | Mont-Saint-Guibert, Belgium | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Qu Biologics Patents
Qu Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025222288-A1 | Immunomodulatory control of metabolic dysregulation | Pending | 23-Apr-2024 | ||
| AU-2022246300-A1 | Perioperative innate immune priming in cancer therapy | Pending | 24-Mar-2021 | ||
| CA-3212380-A1 | Perioperative innate immune priming in cancer therapy | Pending | 24-Mar-2021 | ||
| EP-4313176-A1 | Perioperative innate immune priming in cancer therapy | Pending | 24-Mar-2021 | ||
| EP-4313176-A4 | Perioperative innate immune priming in cancer therapy | Pending | 24-Mar-2021 | A61K35/74 |
Qu Biologics Signals
Qu Biologics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Qu Biologics FAQs
-
When was Qu Biologics founded?
Qu Biologics was founded in 2007.
-
Where is Qu Biologics headquartered?
Qu Biologics is headquartered in Burnaby, Canada.
-
What is the size of Qu Biologics?
Qu Biologics has 11 total employees.
-
What industry is Qu Biologics in?
Qu Biologics’s primary industry is Drug Discovery.
-
Is Qu Biologics a private or public company?
Qu Biologics is a Private company.
-
What is Qu Biologics’s current revenue?
The current revenue for Qu Biologics is .
-
How much funding has Qu Biologics raised over time?
Qu Biologics has raised $65.2M.
-
Who are Qu Biologics’s investors?
Canadian Institutes of Health Research, NRC-IRAP, Curitas Ventures, Harmonix Fund, and Felicity Global Capital are 5 of 6 investors who have invested in Qu Biologics.
-
Who are Qu Biologics’s competitors?
Inovio Pharmaceuticals, Novation Pharmaceuticals, Cellaion, Centrose, and Kite Pharma are some of the 26 competitors of Qu Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process